Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case

Benzinga_recent_news03:25

Avalo Therapeutics Inc.’s (NASDAQ:AVTX) completed enrollment of the Phase 2 LOTUS trial of AVTX-009, the company’s lead drug candidate. The global trial includes approximately 250 adults with moderate...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608656892?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/02/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-02-03 03:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608656892","market":"hk","top_or_hot":-1,"title":"Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case","media":"Benzinga_recent_news","content":"<div>\n<p>Avalo Therapeutics Inc.’s (NASDAQ:AVTX) completed enrollment of the Phase 2 LOTUS trial of AVTX-009, the company’s lead drug candidate.\nThe global trial includes approximately 250 adults with moderate...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50312570/avalo-therapeutics-stock-has-more-than-200-upside-analyst-breaks-down-bull-and-bear-case\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-03 03:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50312570/avalo-therapeutics-stock-has-more-than-200-upside-analyst-breaks-down-bull-and-bear-case><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Avalo Therapeutics Inc.’s (NASDAQ:AVTX) completed enrollment of the Phase 2 LOTUS trial of AVTX-009, the company’s lead drug candidate.\nThe global trial includes approximately 250 adults with moderate...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50312570/avalo-therapeutics-stock-has-more-than-200-upside-analyst-breaks-down-bull-and-bear-case\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50312570/avalo-therapeutics-stock-has-more-than-200-upside-analyst-breaks-down-bull-and-bear-case","article_id":"2608656892","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/02/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50312570/avalo-therapeutics-stock-has-more-than-200-upside-analyst-breaks-down-bull-and-bear-case","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608656892","pubTimestamp":1770060300,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Avalo Therapeutics completed Phase 2 enrollment for AVTX-009, with mid-2026 data ahead. Cantor sees major upside if results impress, but warns shares could plunge if the trial disappoints.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4581":"高盛持仓","BK4139":"生物科技","XBI":"SPDR S&P Biotech ETF","AVTX":"Avalo Therapeutics Inc","BK4007":"制药","LENZ":"Therapeutics","BK4539":"次新股"},"translate_title":"Avalo Therapeutics股票上涨空间超过200%？分析师分析牛市和熊市情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVTX":1,"LENZ":1.5,"XBI":1},"content_text":"Avalo Therapeutics Inc.’s (NASDAQ:AVTX) completed enrollment of the Phase 2 LOTUS trial of AVTX-009, the company’s lead drug candidate.\nThe global trial includes approximately 250 adults with moderate to severe hidradenitis suppurativa to evaluate the efficacy and safety of subcutaneous bi-weekly and monthly dosing regimens compared to placebo.\nTopline data is expected in mid-2026.\nCantor hosted Avalo Therapeutics management. Cantor highlights that if the stock fails stock could sink around 85-90%.\nAnalyst Agarwal sees stock upside even if the HiSCR75 change is around 18%-19%, but the upside is capped as some investors may see the Phase 3 trial as a risk due to efficacy downgrade from Phase 2 to Phase 3.\nHiSCR75 (Hidradenitis Suppurativa Clinical Response 75) is defined as greater than or equal to 75 % reduction in the total abscess and inflammatory nodule count from baseline, with no increase in the number of abscesses or draining tunnels.\nIf the change is between 20-25%, the stock could jump rally 100-150%, and if it falls, the range of 25-30%, Avalo Therapeutics’ stock could skyrocket over 200%.\nCantor analyst Prakhar Agarwal notes that the stock has underperformed when compared to the State Street SPDR S&P Biotech ETF (XBI), which has jumped 2%.\nYear-to-date, Avalo Therapeutics’ stock fell around 13%.\nThe company’s management ‘flagged superior affinity’ for AVTX009 as the biggest competitive advantage, which should lead to a stronger IL-1b inhibition for AVTX009 for a longer time.\nCantor maintains the Overweight rating for Avalo Therapeutics.\nAVTX has seen a positive trend in analyst ratings recently, with firms such as Guggenheim and HC Wainwright & Co. initiating coverage and reiterating a ‘Buy’ rating. \nOn February 2, Guggenheim initiated coverage on AVTX and set a target price of $50.00, the highest target set in the recent months, indicating a bullish outlook for the company.\nEarlier, on January 15, HC Wainwright & Co. reiterated a ‘Buy’ rating, maintaining a $25.00 target that was first established in September. Mizuho also initiated coverage on AVTX in December, giving an ‘Outperform’ rating with a $39.00 target. \nMeanwhile, BTIG reiterated a ‘Buy’ rating on September 29, setting a target at $40.00.\nPrice Action: AVTX stock is up 4.57% at $15.80 at the last check on Monday, according to Benzinga Pro data.\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608656892","isCrawlerRequest":true}